RNLXY · Renalytix plc
$2.00
+0.04 (+2.04%)
At close · Jul 21
Going-concern doubt
— flagged Nov 19, 2024
Substantial doubt about the company's ability to continue as a going concern.
“The Company has incurred recurring losses and negative cash flows from operations since inception and had an accumulated deficit of $216.5 million as of September 30, 2024. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of kidneyintelX.dkd or KidneyIntelX technology services income.”View the 10-Q filed Nov 19, 2024
Market Cap
$662.41M
Shares
331.21M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| James McCullough | CEO | $780,110 |
| Thomas McLain | President | $761,681 |
| O. James Sterling | CFO | $467,205 |
| Fergus Fleming | CTO | $425,702 |
| Michael J. Donovan | Chief Medical Officer | $380,014 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| James McCullough | CEO | $1,036,321 |
| Thomas McLain | President | $662,701 |
| O. James Sterling | CFO | $623,677 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| James McCullough | CEO | $636,011 |
| O. James Sterling | CFO | $461,337 |
| Thomas McLain | President | $443,593 |